Repeat resection emphasized in new bladder cancer guideline

Among the many recommendations within the new AUA guideline for the management of nonmuscle-invasive bladder cancer, arguably one of the most important is the idea of repeating resection for patients with high-grade Ta or T1 disease within a few weeks of the initial resection before making a treatment recommendation.

Related Videos

Related Content

Advertisement

February 6th 2025

Anktiva as a lymphocyte rescue molecule: Unlocking the power of NK cells and T cells

Patrick Soon-Shiong, MD

"One way to think about how Anktiva works is it is the first molecule, based on the package insert, that increases and proliferates the NK cells, the T cells, and the CD4+ and CD8+ T cells, without up-regulating the suppressive T cells," says Patrick Soon-Shiong, MD.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 5th 2025

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

Hannah Clarke

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke

The primary end point is 12-month radiographic progression-free survival.

Related Content

Advertisement

February 6th 2025

Anktiva as a lymphocyte rescue molecule: Unlocking the power of NK cells and T cells

Patrick Soon-Shiong, MD

"One way to think about how Anktiva works is it is the first molecule, based on the package insert, that increases and proliferates the NK cells, the T cells, and the CD4+ and CD8+ T cells, without up-regulating the suppressive T cells," says Patrick Soon-Shiong, MD.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 5th 2025

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

Hannah Clarke

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke

The primary end point is 12-month radiographic progression-free survival.